Phase III OS results are a major clinical milestone and can drive significant re-pricing and future regulatory/commercial expectations; however, the dashboard active symbol list provided does not include SMMT, so no ticker mapping is available.
Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC Maham Fatima Thu, June 4, 2026 at 11:05 AM GMT+2 1 min read SMMT Summit Therapeutics Inc. (NASDAQ: SMMT ) is one of the best high short interest stocks with highest upside potential . On May 31, Summit Therapeutics announced positive Phase III overall survival/OS results from the HARMONi-6 trial, which evaluated ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in patients with advanced squamous non-small cell lung cancer/NSCLC.
The study showed that the ivonescimab regimen reduced the risk of death by 34% (HR 0. 66), marking the first time a Phase III trial has shown a statistically significant OS benefit over standard PD-(L)1 inhibitor and chemotherapy combinations in the first-line setting. At a median follow-up of 21.
4 months, patients receiving ivonescimab achieved a median OS of 27. 89 months compared to 23. 69 months for those on the tislelizumab regimen.
The benefit was consistent across PD-L1 expression subgroups, and the 24-month OS rate reached 64. 7% for the ivonescimab arm. Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC These findings, simultaneously published in The Lancet, confirm the potential of ivonescimab to transform front-line treatment paradigms for NSCLC.
Ivonescimab maintained an acceptable and manageable safety profile consistent with prior trials, with no new safety signals reported. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical firm.
While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .
Disclosure: None. Follow Insider Monkey on Google News .
Oraklio AI Trading Intelligence
Oraklio turns news, price data, and market signals into structured BUY / SELL / NO_TRADE calls - updated continuously throughout the trading day.
Get started freeAlready have an account? Sign in →